These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36470873)

  • 1. Mechanistic investigation of SARS-CoV-2 main protease to accelerate design of covalent inhibitors.
    Kim H; Hauner D; Laureanti JA; Agustin K; Raugei S; Kumar N
    Sci Rep; 2022 Dec; 12(1):21037. PubMed ID: 36470873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking.
    Vázquez-Mendoza LH; Mendoza-Figueroa HL; García-Vázquez JB; Correa-Basurto J; García-Machorro J
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the binding energetics of reversible covalent inhibitors of the SARS-CoV-2 main protease: an
    Awoonor-Williams E
    Phys Chem Chem Phys; 2022 Oct; 24(38):23391-23401. PubMed ID: 36128834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the Main Protease of SARS-CoV-2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors.
    Breidenbach J; Lemke C; Pillaiyar T; Schäkel L; Al Hamwi G; Diett M; Gedschold R; Geiger N; Lopez V; Mirza S; Namasivayam V; Schiedel AC; Sylvester K; Thimm D; Vielmuth C; Phuong Vu L; Zyulina M; Bodem J; Gütschow M; Müller CE
    Angew Chem Int Ed Engl; 2021 Apr; 60(18):10423-10429. PubMed ID: 33655614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and characterization of naturally occurring covalent inhibitors of SARS-CoV-2 M
    Hu Q; Zhang Y; Chen P; Zhang Y; Zhu G; Liu W; Wang C; Zheng S; Shen N; Wang H; Huang P; Ge G
    Chin J Nat Med; 2024 Sep; 22(9):797-807. PubMed ID: 39326974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. De novo design of SARS-CoV-2 main protease inhibitors with characteristic binding modes.
    Zhu Y; Meng J; Feng B; Zhao Y; Zang Y; Lu L; Su M; Yang Q; Zhang Q; Feng L; Zhao J; Shao M; Ma Y; Yang X; Yang H; Li J; Jiang X; Rao Z
    Structure; 2024 Sep; 32(9):1327-1334.e3. PubMed ID: 38925121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of SARS-CoV-2 main protease inhibitor using structure-based virtual screening.
    Hakami AR; Bakheit AH; Almehizia AA; Ghazwani MY
    Future Med Chem; 2022 Jan; 14(2):61-79. PubMed ID: 34814706
    [No Abstract]   [Full Text] [Related]  

  • 8. Discovery of SARS-CoV-2 main protease covalent inhibitors from a DNA-encoded library selection.
    Ge R; Shen Z; Yin J; Chen W; Zhang Q; An Y; Tang D; Satz AL; Su W; Kuai L
    SLAS Discov; 2022 Mar; 27(2):79-85. PubMed ID: 35063690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-silico pharmacophoric and molecular docking-based drug discovery against the Main Protease (Mpro) of SARS-CoV-2, a causative agent COVID-19.
    Haider Z; Subhani MM; Farooq MA; Ishaq M; Khalid M; Akram MN; Khan RSA; Niazi AK
    Pak J Pharm Sci; 2020 Nov; 33(6):2697-2705. PubMed ID: 33867348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docking-based virtual screening studies aiming at the covalent inhibition of SARS-CoV-2 M
    Soulère L; Barbier T; Queneau Y
    Comput Biol Chem; 2021 Jun; 92():107463. PubMed ID: 33677227
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Bung N; Krishnan SR; Bulusu G; Roy A
    Future Med Chem; 2021 Mar; 13(6):575-585. PubMed ID: 33590764
    [No Abstract]   [Full Text] [Related]  

  • 12. A Review of the Current Landscape of SARS-CoV-2 Main Protease Inhibitors: Have We Hit the Bullseye Yet?
    Macip G; Garcia-Segura P; Mestres-Truyol J; Saldivar-Espinoza B; Pujadas G; Garcia-Vallvé S
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Easy access to α-ketoamides as SARS-CoV-2 and MERS M
    Pelliccia S; Cerchia C; Esposito F; Cannalire R; Corona A; Costanzi E; Kuzikov M; Gribbon P; Zaliani A; Brindisi M; Storici P; Tramontano E; Summa V
    Eur J Med Chem; 2022 Dec; 244():114853. PubMed ID: 36332546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Se-S Bond Formation in the Covalent Inhibition Mechanism of SARS-CoV-2 Main Protease by Ebselen-like Inhibitors: A Computational Study.
    Parise A; Romeo I; Russo N; Marino T
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reconstruction of the unbinding pathways of noncovalent SARS-CoV and SARS-CoV-2 3CLpro inhibitors using unbiased molecular dynamics simulations.
    Noroozi Tiyoula F; Aryapour H
    PLoS One; 2022; 17(2):e0263251. PubMed ID: 35139108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Updated Review on SARS-CoV-2 Main Proteinase (M
    Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
    Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease.
    Dou X; Sun Q; Xu G; Liu Y; Zhang C; Wang B; Lu Y; Guo Z; Su L; Huo T; Zhao X; Wang C; Yu Z; Song S; Zhang L; Liu Z; Lai L; Jiao N
    Eur J Med Chem; 2022 Aug; 238():114508. PubMed ID: 35688005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An integrated metabolomic and proteomic approach for the identification of covalent inhibitors of the main protease (M
    Baron G; Borella S; Della Vedova L; Vittorio S; Vistoli G; Carini M; Aldini G; Altomare A
    Talanta; 2023 Jan; 252():123824. PubMed ID: 36027618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease.
    Su H; Yao S; Zhao W; Zhang Y; Liu J; Shao Q; Wang Q; Li M; Xie H; Shang W; Ke C; Feng L; Jiang X; Shen J; Xiao G; Jiang H; Zhang L; Ye Y; Xu Y
    Nat Commun; 2021 Jun; 12(1):3623. PubMed ID: 34131140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MPI8 is Potent against SARS-CoV-2 by Inhibiting Dually and Selectively the SARS-CoV-2 Main Protease and the Host Cathepsin L.
    Ma XR; Alugubelli YR; Ma Y; Vatansever EC; Scott DA; Qiao Y; Yu G; Xu S; Liu WR
    ChemMedChem; 2022 Jan; 17(1):e202100456. PubMed ID: 34242492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.